Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL6467968

CCN(CC)CCOc1ccc2nc(Nc3nc(C)c4cc(OC)c(OC)cc4n3)nc(O)c2c1.O=C(O)C(F)(F)F

nearest known ligand 0.43

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 10/20 0.41
MEN1 O00255 2/20 0.38
ALDH1A1 P00352 2/20 0.38
KMT2A Q03164 2/20 0.38
KDM4E B2RXH2 1/20 0.38
PSMD14 O00487 1/20 0.38
APAF1 O14727 1/20 0.38
MITF O75030 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
PTK2B Q14289 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
USP2 O75604 1/20 0.38
LMNA P02545 1/20 0.38
RAB9A P51151 1/20 0.38
ESR1 P03372 1/20 0.38
EBP Q15125 1/20 0.38
ESR2 Q92731 1/20 0.38
DHCR7 Q9UBM7 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL6467347 0.95 FGFR2 (0.38) KDRMEN1ALDH1A1KMT2AKDM4E
Trifluoroacetic Acid SCHEMBL6469301 0.95 KDR (0.37) KDRMEN1ALDH1A1KMT2AKDM4E
SCHEMBL6468013 0.93 KDR (0.41) KDRMEN1ALDH1A1KMT2AKDM4E
Trifluoroacetic Acid SCHEMBL6467438 0.93 FGFR2 (0.41) MEN1ALDH1A1KMT2AKDM4EPSMD14
Trifluoroacetic Acid SCHEMBL6469711 0.92 RET (0.39) MEN1ALDH1A1KMT2AKDM4EPSMD14
Trifluoroacetic Acid SCHEMBL6470895 0.90 MEN1 (0.37) KDRMEN1ALDH1A1KMT2AKDM4E
Trifluoroacetic Acid SCHEMBL6467159 0.89 ALDH1A1 (0.38) MEN1ALDH1A1KMT2AKDM4EPSMD14
Trifluoroacetic Acid SCHEMBL6467465 0.89 MAPT (0.39) MEN1ALDH1A1KMT2AKDM4EPSMD14
Trifluoroacetic Acid SCHEMBL6466263 0.89 MAPT (0.40) MEN1ALDH1A1KMT2AKDM4EPSMD14
Trifluoroacetic Acid SCHEMBL6465761 0.89 AURKA (0.39) KDRMEN1ALDH1A1KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US claimed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO claimed
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections REPLIDYNE, INC. 2005-06-09 US disclosed
WO-2005030131-A2 BIS-QUINAZOLINE COMPOUNDS FOR THE TREATMENT OF BACTERIAL INFECTIONS REPLIDYNE, INC (US) 2005-04-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050124562-A1 Bis-quinazoline compounds for the treatment of bacterial infections POLI, POLK, POLB KDR 4703/4885MEN1 4218/4885ALDH1A1 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.